CD markers

Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy.

Amulirafusp alfa is an anti-MS4A1/CD47 IgG1κ type human antibody designed to target the MS4A1/CD47 axis. This antibody exhibits key biological activity by antagonizing CD47-mediated immune evasion, thereby enhancing phagocytosis and promoting anti-tumor immunity. It is suitable for applications in cancer immunotherapy research and studies exploring immune cell interactions in various disease models.

TQB-2928 is a monoclonal antibody targeting CD47, a prominent regulator of immune evasion in cancer cells. This reagent plays a crucial role in research focused on cancer immunotherapy by blocking the "don't eat me" signal that CD47 transmits to macrophages. TQB-2928 is essential for studying tumor microenvironments, immune responses, and developing therapeutic strategies aimed at enhancing anti-tumor immunity.

Pep-20 is a CD47/SIRPα blocking peptide that inhibits the interaction between CD47 and SIRPα, demonstrating KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. With IC50 values of 24.56 μM and 12.03 μM, respectively, for blocking these interactions, Pep-20 exhibits significant anti-tumor activity. This peptide is useful in research applications focused on immune evasion in cancer therapies and interactions within the tumor microenvironment.

NCGC00138783 free base is a selective blocker of the CD47/SIRPα interaction, exhibiting an IC50 of 50 µM. By inhibiting this axis, NCGC00138783 free base promotes immune cell activation, making it a valuable tool for research in cancer immunotherapy and immune modulation studies. Its ability to disrupt CD47 signaling can facilitate investigations into tumor evasion mechanisms and potential therapeutic strategies.

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody that targets the CD47-SIRPα interaction to induce tumor phagocytosis. This antibody preferentially binds to tumor cells over normal cells and promotes tumor cell death through a direct mechanism, independent of antibody-dependent cell-mediated cytotoxicity (ADCC). AO-176 exhibits dose-dependent antitumor effects in tumor xenograft models, making it a valuable tool for cancer research, particularly in studies involving lymphoma.

EP 80317 is a selective ligand for CD36. This compound exhibits cardioprotective effects against damage and dysfunction caused by myocardial ischemia and reperfusion, while also temporarily reducing peripheral lipolysis. EP 80317 is valuable in the investigation of cardiovascular disease mechanisms and potential therapeutic interventions.